




The Intellectual Property Engine for Drug Discovery



Press Release

BioLeap wins GlaxoSmithKline contract to design novel lead compounds for previously intractable targets for important unmet medical needs.

BioLeap and GSK have entered into an agreement whereby BioLeap will design novel lead compounds for "difficult" drug targets. The targets (not disclosed) are ones for which conventional approaches, like high throughput screening, have failed to yield a viable chemical starting point. Typically these are in areas of high unmet medical need.

BioLeap will use its computational fragment-based drug design platform to conceive compounds de novo that are molecularly tailored to bind to the target. GSK will synthesize and test the compounds in biochemical and cellular assays. The process will iterate until GSK selects a Lead Candidate. The terms of the agreement for services were not disclosed.

David Pompliano, PhD, CEO of BioLeap said, "We are very pleased to be working with GSK to accelerate the discovery of truly novel medicines. BioLeap's platform reliably predicts the effect of compound modifications on target affinity, thus minimizing unproductive guesswork during drug discovery, and producing a better drug candidate more quickly."

About BioLeap

BioLeap is a leader in computational fragment-based drug design. The company's proprietary design technology and process successfully addresses one of the biggest problems in pre-clinical drug discovery: the limitation of drug like and patentable leads for important biological targets. BioLeap is using its completely "in-silico" platform to quickly and accurately predict fragment-protein binding information that provides drug designers new insights that enable them to efficiently create new and improved drug molecule candidates. The BioLeap computational approach addresses the time, cost, and low probability of success limitations imposed by traditional library screening and lead optimization methods. BioLeap is utilizing its capabilities to advance its own internal preclinical stage programs while collaboratively enabling non-competing programs with numerous pharmaceutical partners.

Contact:

BioLeap, LLC

Gerry Evans

215-371-2874

ghe@bioleap.com

346A Lurgan Road
New Hope, PA 18938

215-371-2874 / info@bioleap.com / www.bioleap.com